Stocks Health care MENS
NASDAQ · Health careJyong Biotech Ltd. (MENS)
It posted a net loss of $4.7M. At December 31, 2025 it held $1.2M in cash against $2.1M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on May 15, 2026.
Key facts about Jyong Biotech Ltd.
- Net worth
- Jyong Biotech Ltd. has a market value (market cap) of $136.1M at the latest share price, and shareholders' equity of -$24.9M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $3M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on May 15, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Jyong Biotech Ltd. does
Jyong Biotech Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MENS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$4.7M | -$0.06 | n/a |
| 2025 | n/a | -$3M | -$0.04 | n/a |
| 2023 | n/a | -$4.4M | -$0.06 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Jyong Biotech Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- May 15, 2026
- April 29, 2026Form NT 20-F filing NT 20-F
- April 24, 2026Activist stake (5% or more) SCHEDULE 13D
- February 6, 2026
- January 9, 2026
- June 30, 2025Form SP 15D2 filing SP 15D2
- June 20, 2025
- June 6, 2025Form POS AM filing POS AM
- April 23, 2025Form POS AM filing POS AM
- March 11, 2025
Insider trades
What the people running Jyong Biotech Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns MENS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Perfect Minds Co., Ltd13D, may seek influence with 3 related filers | 33.34% | April 24, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 19 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 260,317 | +1,557 |
| Geode Capital Management, LLC | 68,882 | +4,650 |
| XTX Topco Ltd | 29,066 | new |
| Renaissance Technologies LLC | 22,900 | new |
| China Universal Asset Management Co., Ltd. | 12,100 | -1,073 |
| State of Wyoming | 11,208 | new |
| Morgan Stanley | 6,112 | -189 |
| Barclays PLC | 5,931 | +742 |
| Jpmorgan Chase & Co | 5,379 | -300 |
| UBS Group AG | 4,046 | -33,317 |
| Mirae Asset Global Investments Co., Ltd. | 3,400 | -472 |
| Bnp Paribas Financial Markets | 2,710 | +829 |
| Citigroup Inc | 2,501 | -286 |
| GF Fund Management Co. Ltd. | 1,559 | -118 |
| Tower Research Capital LLC (TRC) | 1,070 | -10,633 |
| Cornerstone Financial Management LLC | 234 | new |
| Bell Investment Advisors, Inc | 206 | -267 |
| Hrt Financial LP | 50,423 | +38,656 |
| Caitong International Asset Management Co., Ltd | 9 | new |
Insiders
Questions about MENS
What does Jyong Biotech Ltd. do?
Jyong Biotech Ltd. is a company in the Health care sector, listed on NASDAQ as MENS. Its shares trade on NASDAQ under the ticker MENS.
What is Jyong Biotech Ltd.'s net worth?
Jyong Biotech Ltd. has a market value (market cap) of $136.1M at the latest share price, and shareholders' equity of -$24.9M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Jyong Biotech Ltd. profitable?
No. In fiscal 2025 it reported a net loss of $4.7M.
When did Jyong Biotech Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on May 15, 2026. It covers the period to December 31, 2025.
Similar companies
Compare MENS with
Follow MENS
Get an email when Jyong Biotech Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Jyong Biotech Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.